Cancer Research and Treatment

Original Articles

Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05): Inkeun Park, Shinkyo Yoon, Ilhwan Kim, Kwonoh Park, Suee Lee, Bhumsuk Keam, Joo-Hwan Park, Jin Young Kim, Yoon Ji Choi, Byeong Seok Sohn, Jae Lyun Lee; Received October 16, 2024 Accepted December 26, 2024 Published online December 27, 2024; DOI: https://doi.org/10.4143/crt.2024.1003 [Epub ahead of print]

Abstract PDF PubReader ePub: Purpose
Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
Materials and Methods
Eligible aUC patients who did not progress after 4-6 cycles of cisplatin or carboplatin-based chemotherapy were randomized 1:1 to receive maintenance pemetrexed (500 mg/m² intravenously every 3 weeks, up to 16 cycles) or observation. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response rate, and safety.
Results
The trial was closed early due to slow accrual after avelumab approval. From October 2016 to December 2022, 97 patients were randomized to pemetrexed (n=49) or observation (n=48). The median age was 69 years (range, 43 to 90) and 66 (range, 33 to 82), respectively, with 63% and 73% of patients being male, respectively. The median PFS was 6.0 months (95% confidence interval [CI], 3.4 to 8.5) with pemetrexed versus 2.3 months (95% CI, 1.8 to 2.7) with observation (p=0.044; hazard ratio [HR], 0.64; 95% CI, 0.41 to 0.99). The median OS was 18.1 months (95% CI, 6.9 to 29.4) for pemetrexed and 17.9 months (95% CI, 16.1 to 19.7) for observation (p=0.913; HR, 1.03; 95% CI, 0.61 to 1.73). Common adverse events in the pemetrexed group included anemia (30.6%), fatigue (18.4%), and neutropenia (12.2%), primarily grade 1 or 2.
Conclusion
The PREMIER trial showed that switch maintenance pemetrexed significantly prolonged PFS in aUC patients post-1L platinum-based chemotherapy, with a favorable safety profile. Further studies on combination maintenance therapies are warranted.

753 View
60 Download

General

Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations: Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Seungtaek Lim, Sung Shim Cho, Jang Ho Cho, Sang Won Shin, Kyong Hwa Park, Yeul Hong Kim; Cancer Res Treat. 2022;54(1):30-39. Published online May 20, 2021; DOI: https://doi.org/10.4143/crt.2021.218

Abstract PDF PubReader ePub

Purpose
K-MASTER project is a Korean national precision medicine platform that screened actionable mutations by analyzing next-generation sequencing (NGS) of solid tumor patients. We compared gene analyses between NGS panel from the K-MASTER project and orthogonal methods.
Materials and Methods
Colorectal, breast, non–small cell lung, and gastric cancer patients were included. We compared NGS results from K-MASTER projects with those of non-NGS orthogonal methods (KRAS, NRAS, and BRAF mutations in colorectal cancer [CRC]; epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK] fusion, and reactive oxygen species 1 [ROS1] fusion in non–small cell lung cancer [NSCLC], and Erb-B2 receptor tyrosine kinase 2 (ERBB2) positivity in breast and gastric cancers).
Results
In the CRC cohort (n=225), the sensitivity and specificity of NGS were 87.4% and 79.3% (KRAS); 88.9% and 98.9% (NRAS); and 77.8% and 100.0% (BRAF), respectively. In the NSCLC cohort (n=109), the sensitivity and specificity of NGS for EGFR were 86.2% and 97.5%, respectively. The concordance rate for ALK fusion was 100%, but ROS1 fusion was positive in only one of three cases that were positive in orthogonal tests. In the breast cancer cohort (n=260), ERBB2 amplification was detected in 45 by NGS. Compared with orthogonal methods that integrated immunohistochemistry and in situ hybridization, sensitivity and specificity were 53.7% and 99.4%, respectively. In the gastric cancer cohort (n=64), ERBB2 amplification was detected in six by NGS. Compared with orthogonal methods, sensitivity and specificity were 62.5% and 98.2%, respectively.
Conclusion
The results of the K-MASTER NGS panel and orthogonal methods showed a different degree of agreement for each genetic alteration, but generally showed a high agreement rate.

Citations

Citations to this article as recorded by

Genomic Profiling of Driver Gene Alterations in Patients With Non–Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients
Minit Shah, Vanita Noronha, Vijay Patil, Ajay Kumar Singh, Nandini Menon, Supriya Goud, Srushti Shah, Sucheta More, Akhil Kapoor, Bal Krishna Mishra, Pratik Chandrani, Anuradha Chougule, Vinod Gupta, Priyanka Pange, Omshree Shetty, Trupti Pai, Rajiv Kaush
Clinical Lung Cancer.2025; 26(4): e270. CrossRef
Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer
Yonghwa Choi, Jangwoo Lee, Keewon Shin, Ji Won Lee, Ju Won Kim, Soohyeon Lee, Yoon Ji Choi, Kyong Hwa Park, Jwa Hoon Kim
BMC Cancer.2024;[Epub] CrossRef
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
Albrecht Stenzinger, Brian Cuffel, Noman Paracha, Eric Vail, Jesus Garcia-Foncillas, Clifford Goodman, Ulrik Lassen, Gilles Vassal, Sean D Sullivan
The Oncologist.2023; 28(5): e242. CrossRef
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
Scientific Reports.2023;[Epub] CrossRef
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se
Cancer Research and Treatment.2022; 54(1): 1. CrossRef

9,266 View
265 Download
6 Web of Science
5 Crossref

Gastrointestinal cancer

Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project: Youngwoo Lee, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Ah-reum Lim, Ju Won Kim, Yoon Ji Choi, Kyong Hwa Park, Yeul Hong Kim; Cancer Res Treat. 2021;53(1):123-130. Published online August 18, 2020; DOI: https://doi.org/10.4143/crt.2020.559

Abstract PDF Supplementary Material PubReader ePub

Purpose
Next-generation sequencing (NGS) can facilitate precision medicine approaches in metastatic colorectal cancer (mCRC) patients. We investigated the molecular profiling of Korean mCRC patients under the K-MASTER project which was initiated in June 2017 as a nationwide precision medicine oncology clinical trial platform which used NGS assay to screen actionable mutations.
Materials and Methods
As of 22 January 2020, total of 994 mCRC patients were registered in K-MASTER project. Targeted sequencing was performed using three platforms which were composed of the K-MASTER cancer panel v1.1 and the SNUH FIRST Cancer Panel v3.01. If tumor tissue was not available, cell-free DNA was extracted and the targeted sequencing was performed by Axen Cancer Panel as a liquid biopsy.
Results
In 994 mCRC patients, we found 1,564 clinically meaningful pathogenic variants which mutated in 71 genes. Anti-EGFR therapy candidates were 467 patients (47.0%) and BRAF V600E mutation (n=47, 4.7%), deficient mismatch repair/microsatellite instability–high (n=15, 1.5%), HER2 amplifications (n=10, 1.0%) could be incorporated with recently approved drugs. The patients with high tumor mutation burden (n=101, 12.7%) and DNA damaging response and repair defect pathway alteration (n=42, 4.2%) could be enrolled clinical trials with immune checkpoint inhibitors. There were more colorectal cancer molecular alterations such as PIK3CA, KRAS G12C, atypical BRAF, and HER2 mutations and even rarer but actionable genes that approved or ongoing clinical trials in other solid tumors.
Conclusion
K-MASTER project provides an intriguing background to investigate new clinical trials with biomarkers and give therapeutic opportunity for mCRC patients.

Citations

Citations to this article as recorded by

Tumor mutational burden in colorectal cancer: Implications for treatment
Adriana Marques, Patrícia Cavaco, Carla Torre, Bruno Sepodes, João Rocha
Critical Reviews in Oncology/Hematology.2024; 197: 104342. CrossRef
Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer
Yonghwa Choi, Jangwoo Lee, Keewon Shin, Ji Won Lee, Ju Won Kim, Soohyeon Lee, Yoon Ji Choi, Kyong Hwa Park, Jwa Hoon Kim
BMC Cancer.2024;[Epub] CrossRef
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
Cancer Research and Treatment.2023; 55(2): 531. CrossRef
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
Scientific Reports.2023;[Epub] CrossRef
Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations
Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Se
Cancer Research and Treatment.2022; 54(1): 30. CrossRef
Genetic landscape of pancreatic adenocarcinoma patients: a pilot study from Pakistan
Saleema Mehboob Ali, Yumna Adnan, Zubair Ahmad, Hasnain Ahmed Farooqui, Tabish Chawla, S. M. Adnan Ali
Molecular Biology Reports.2022; 49(2): 1341. CrossRef
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se
Cancer Research and Treatment.2022; 54(1): 1. CrossRef
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won L
The Breast.2022; 65: 172. CrossRef
The importance of precision medicine in modern molecular oncology
Yuanli Wang, Dawu Zheng
Clinical Genetics.2021; 100(3): 248. CrossRef
Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
BMB Reports.2021; 54(7): 386. CrossRef
Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer
Aitor Rodríguez-Casanova, Aida Bao-Caamano, Ramón M. Lago-Lestón, Elena Brozos-Vázquez, Nicolás Costa-Fraga, Isabel Ferreirós-Vidal, Ihab Abdulkader, Yolanda Vidal-Insua, Francisca Vázquez Rivera, Sonia Candamio Folgar, Rafael López-López, Laura Muinelo-R
Journal of Clinical Medicine.2021; 10(19): 4487. CrossRef
Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
Saikat Chowdhury, Matan Hofree, Kangyu Lin, Dipen Maru, Scott Kopetz, John Paul Shen
Cancers.2021; 13(19): 4923. CrossRef

10,857 View
363 Download
13 Web of Science
12 Crossref

Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer: Jung Yoon Choi, Sunho Choi, Minhyeok Lee, Young Soo Park, Jae Sook Sung, Won Jin Chang, Ju Won Kim, Yoon Ji Choi, Jin Kim, Dong-Sik Kim, Sung-Ho Lee, Junhee Seok, Kyong Hwa Park, Seon Hahn Kim, Yeul Hong Kim; Cancer Res Treat. 2020;52(3):764-778. Published online February 16, 2020; DOI: https://doi.org/10.4143/crt.2020.044

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to identify the concordant or discordant genomic profiling between primary and matched metastatic tumors in patients with colorectal cancer (CRC) and to explore the clinical implication.
Materials and Methods
Surgical samples of primary and matched metastatic tissues from 158 patients (335 samples) with CRC at Korea University Anam Hospital were evaluated using the Ion AmpliSeq Cancer Hotspot Panel. We compared genetic variants and classified them as concordant, primary-specific, and metastasis-specific variants. We used a combination of principal components analysis and clustering to find genomic groups. Kaplan-Meier curves were used to appraise survival between genomic groups. We used machine learning to confirm the correlation between genetic variants and metastatic sites.
Results
A total of 282 types of deleterious non-synonymous variants were selected for analysis. Of a total of 897 variants, an average of 40% was discordant. Three genomic groups were yielded based on the genomic discrepancy patterns. Overall survival differed significantly between the genomic groups. The poorest group had the highest proportion of concordant KRAS G12V and additional metastasis-specific SMAD4. Correlation analysis between genetic variants and metastatic sites suggested that concordant KRAS mutations would have more disseminated metastases.
Conclusion
Driver gene mutations were mostly concordant; however, discordant or metastasis-specific mutations were present. Clinically, the concordant driver genetic changes with additional metastasis-specific variants can predict poor prognosis for patients with CRC.

Citations

Citations to this article as recorded by

Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients
Heather Johnson, Zahra El-Schich, Amjad Ali, Xuhui Zhang, Athanasios Simoulis, Anette Gjörloff Wingren, Jenny L. Persson
Cancers.2022; 14(8): 2045. CrossRef
Putative anoikis resistant subpopulations are enriched in lymph node metastases and indicate adverse prognosis in colorectal carcinoma
Taneli T. Mattila, Madhura Patankar, Juha P. Väyrynen, Kai Klintrup, Jyrki Mäkelä, Anne Tuomisto, Pentti Nieminen, Markus J. Mäkinen, Tuomo J. Karttunen
Clinical & Experimental Metastasis.2022; 39(6): 883. CrossRef
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project
Youngwoo Lee, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Ah-reum Lim, Ju Won Kim, Yoon Ji Choi, Kyong Hwa Park, Yeul Hong Kim
Cancer Research and Treatment.2021; 53(1): 123. CrossRef
Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
Zhengquan Xu, Yanhong Ding, Wei Lu, Ke Zhang, Fei Wang, Guanxiong Ding, Jianqing Wang
PeerJ.2021; 9: e11133. CrossRef
High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer
Seung Eun Lee, Ha Young Park, Dae-Yong Hwang, Hye Seung Han
International Journal of Molecular Sciences.2021; 22(11): 5561. CrossRef
Comprehensive Imaging Characterization of Colorectal Liver Metastases
Drew Maclean, Maria Tsakok, Fergus Gleeson, David J. Breen, Robert Goldin, John Primrose, Adrian Harris, James Franklin
Frontiers in Oncology.2021;[Epub] CrossRef

8,980 View
202 Download
6 Web of Science
6 Crossref

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05): Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park; Cancer Res Treat. 2018;50(4):1252-1259. Published online January 2, 2018; DOI: https://doi.org/10.4143/crt.2017.438

Abstract PDF PubReader ePub

Purpose
Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR). We evaluated the efficacy and toxicity of dovitinib in men with metastatic castration resistant prostate cancer (mCRPC).
Materials and Methods
This study was a single-arm, phase II, open-label, multicenter trial of dovitinib 500 mg/day (5-days-on/2-days-off schedule). The primary endpointwas 16-week progression-free survival (PFS). Secondary endpoints were overall survival (OS), toxicity and prostate-specific antigen (PSA) response rate. Biomarker analyses for VEGFR2, FGF23, and FGFR2 using multiplex enzyme-linked immunosorbent assay was performed.
Results
Forty-four men were accrued from 11 hospitals. Eighty percent were post-docetaxel. Median PSA was 100 ng/dL, median age was 69, 82% had bone metastases, and 23% had liver metastases. Median cycles of dovitinibwas 2 (range, 0 to 33). Median PFSwas 3.67 months (95% confidence interval [CI], 1.36 to 5.98) and median OS was 13.70 months (95% CI, 0 to 27.41). Chemotherapy-naïve patients had longer PFS (17.90 months; 95% CI, 9.23 to 28.57) compared with docetaxel-treated patients (2.07 months; 95% CI, 1.73 to 2.41; p=0.001) and the patients with high serum VEGFR2 level over median level (7,800 pg/mL) showed longer PFS compared with others (6.03 months [95% CI, 4.26 to 7.80] vs. 1.97 months [95% CI, 1.79 to 2.15], p=0.023). Grade 3 related adverse events were seen in 40.9% of patients. Grade 1-2 nausea, diarrhea, fatigue, anorexia, and all grade thrombocytopenia are common.
Conclusion
Dovitinib showed modest antitumor activity with manageable toxicities in men with mCRPC. Especially, patients who were chemo-naïve benefitted from dovitinib.

Citations

Citations to this article as recorded by

Invasion and metastasis in cancer: molecular insights and therapeutic targets
Yongxing Li, Fengshuo Liu, Qingjin Cai, Lijun Deng, Qin Ouyang, Xiang H.-F. Zhang, Ji Zheng
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
Synergistic targeting strategies for prostate cancer
Xuanji Li, Zeyu Han, Jianzhong Ai
Nature Reviews Urology.2025;[Epub] CrossRef
In vitro cytotoxicity in A549, Hepg2, MCF-7, and DLD-1 cancer cell lines and ADME/toxin analysis of a benzimidazole derivative
Esra Bilici, Senem Akkoc
Journal of King Saud University – Science.2025; 37: 4242024. CrossRef
Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
Manish Chaudhary, Shubham Kumar, Paranjeet Kaur, Sanjeev Kumar Sahu, Amit Mittal
Mini-Reviews in Medicinal Chemistry.2024; 24(7): 721. CrossRef
Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response
Maddison Archer
American Journal of Clinical and Experimental Urology.2024; 12(6): 331. CrossRef
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Alessio Ardizzone, Valentina Bova, Giovanna Casili, Alberto Repici, Marika Lanza, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Salvatore Cuzzocrea, Emanuela Esposito, Irene Paterniti
Cells.2023; 12(7): 1002. CrossRef
Case Report of a Glioma Patient with Homozygous Missense Amino Acid Substitution in KDR Gene
Kalyan Ram Uppaluri, Himavanth Reddy Kambalachenu, Hima Jyothi Challa, Saadvik Raghuram Y., Deepak Sharma, Ramya Gadicherla, Srinivas Ketavath, Kalyani Palasamudram, Sri Manjari K.
Indian Journal of Medical and Paediatric Oncology.2023; 44(03): 356. CrossRef
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu, Weiyi Fang
MedComm.2023;[Epub] CrossRef
Targeting transforming growth factor‐ß signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin
Devesh Tewari, Anu Priya, Anusha Bishayee, Anupam Bishayee
Clinical and Translational Medicine.2022;[Epub] CrossRef
Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines
Katharina Klose, Eva‐Maria Packeiser, José‐Luis Granados‐Soler, Marion Hewicker‐Trautwein, Hugo Murua Escobar, Ingo Nolte
Veterinary and Comparative Oncology.2022; 20(3): 641. CrossRef
Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy
Elizabeth Liow, Nicholas Howard, Chol-Hee Jung, Bernard Pope, Bethany K. Campbell, Anne Nguyen, Michael Kerger, Jonathan B. Ruddle, Angelyn Anton, Benjamin Thomas, Kevin Chu, Philip Dundee, Justin S. Peters, Anthony J. Costello, Andrew S. Ryan, Christophe
Clinical Genitourinary Cancer.2022; 20(5): 452. CrossRef
There are gremlins in prostate cancer
Laura A. Sena, W. Nathaniel Brennen, John T. Isaacs
Nature Cancer.2022; 3(5): 530. CrossRef
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Pankaj Sonawane, Harshali Paliwal, Suresh Thareja, Prateek Pathak, Maria Grishina, Mariusz Jaremko, Abdul-Hamid Emwas, Jagat Pal Yadav, Amita Verma, Habibullah Khalilullah, Pradeep Kumar
Pharmaceuticals.2022; 15(9): 1071. CrossRef
The FGF/FGFR system in the physiopathology of the prostate gland
Arianna Giacomini, Elisabetta Grillo, Sara Rezzola, Domenico Ribatti, Marco Rusnati, Roberto Ronca, Marco Presta
Physiological Reviews.2021; 101(2): 569. CrossRef
Signaling Pathways That Control Apoptosis in Prostate Cancer
Amaal Ali, George Kulik
Cancers.2021; 13(5): 937. CrossRef
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Fionnuala Crowley, Michelle Sterpi, Conor Buckley, Lauren Margetich, Shivani Handa, Zach Dovey
Research and Reports in Urology.2021; Volume 13: 457. CrossRef
Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
F.J. Sherida H. Woei-A-Jin, Nir I. Weijl, Mark C. Burgmans, Arantza Fariña Sarasqueta, J. Tom van Wezel, Martin N.J.M. Wasser, Minneke J. Coenraad, Jacobus Burggraaf, Susanne Osanto
The Oncologist.2021; 26(10): 854. CrossRef
Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment
Peiyuan Zhang, Xiaohui Liu, Daniel Abegg, Toru Tanaka, Yuquan Tong, Raphael I. Benhamou, Jared Baisden, Gogce Crynen, Samantha M. Meyer, Michael D. Cameron, Arnab K. Chatterjee, Alexander Adibekian, Jessica L. Childs-Disney, Matthew D. Disney
Journal of the American Chemical Society.2021; 143(33): 13044. CrossRef
Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer
Clara H. Lee, Ann M. Decker, Frank C. Cackowski, Russell S. Taichman
Cell Biology and Toxicology.2020; 36(2): 115. CrossRef
Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD
Lele Li, Manhui Zhu, Wenli Wu, Bai Qin, Jiayi Gu, Yuanyuan Tu, Jianing Chen, Dong Liu, Yunwei Shi, Xiaojuan Liu, Aimin Sang, Dongmei Ding
Journal of Cellular Physiology.2020; 235(2): 1259. CrossRef
In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
Arabinda Das, Jaime L. Martinez Santos, Mohammed Alshareef, Guilherme Bastos Ferreira Porto, Libby Kosnik Infinger, William A. Vandergrift, Scott M. Lindhorst, Abhay K. Varma, Sunil J. Patel, David Cachia
Cancer Investigation.2020; 38(6): 349. CrossRef
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma
Ling Zhang, Xia Niu, Yanghui Bi, Heyang Cui, Hongyi Li, Xiaolong Cheng
Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer

Adam M. Kase, John A. Copland, Winston Tan
OncoTargets and Therapy.2020; Volume 13: 10499. CrossRef
Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)
Hong Luo, Tao Zhang, Peng Cheng, Dong Li, Oleksandr Ogorodniitchouk, Chaimaa Lahmamssi, Ge Wang, Meiling Lan
Oncology Letters.2020; 20(3): 2525. CrossRef
Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
Yi-Han Chiu, Yi-Yen Lee, Kuo-Chin Huang, Cheng-Chi Liu, Chen-Si Lin
Journal of Oncology.2019; 2019: 1. CrossRef
Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis
Niko Kemi, Maarit Eskuri, Joonas H. Kauppila
Scientific Reports.2019;[Epub] CrossRef
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
Dan Wang, Li Yang, Weina Yu, Yi Zhang
Expert Opinion on Investigational Drugs.2019; 28(10): 903. CrossRef
A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance
Jacqueline Olender, Bi-Dar Wang, Travers Ching, Lana X. Garmire, Kaitlin Garofano, Youngmi Ji, Tessa Knox, Patricia Latham, Kenneth Nguyen, Johng Rhim, Norman H. Lee
Molecular Cancer Research.2019; 17(10): 2115. CrossRef
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Ekaterina Nevedomskaya, Simon J. Baumgart, Bernard Haendler
International Journal of Molecular Sciences.2018; 19(5): 1359. CrossRef

11,607 View
247 Download
31 Web of Science
30 Crossref

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results: Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung; Cancer Res Treat. 2017;49(2):423-429. Published online August 3, 2016; DOI: https://doi.org/10.4143/crt.2016.191

Abstract PDF PubReader ePub

Purpose
Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC),who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials.
Materials and Methods
In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease.
Results
A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively.
Conclusion
This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.

Citations

Citations to this article as recorded by

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
Yu-Ju Lin, Chun-Nan Kuo, Yu Ko
The Breast.2021; 57: 18. CrossRef
Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
Pei-Hsin Chen, Dah-Cherng Yeh, Heng-Hsin Tung, Chin-Yao Lin
Medicine.2021; 100(47): e27859. CrossRef
Multifarious targets beyond microtubules—role of eribulin in cancer therapy
Priya Seshadri, Barnali Deb, Prashant Kumar
Frontiers in Bioscience-Scholar.2021;[Epub] CrossRef
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh, Geumhee Gwak, Tae Hyun Kim, Young Bum Yoo, Hyun-Ah Kim, Min Young Kim, Ju Yeon Kim, Joon Jeong
The Breast.2020; 54: 121. CrossRef
Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu, Ming-Hung Hu, Yin-Che Lu, Wei-Jen Ou, Chin-Ho Kuo, Chieh-Han Chuang, Jung-Yu Kan, Fang-Ming Chen, Ming-Feng Hou
Breast Cancer Research and Treatment.2018; 170(3): 583. CrossRef
Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2018; 128: 110. CrossRef
Angiomodulators in cancer therapy: New perspectives
Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Büsselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak
Biomedicine & Pharmacotherapy.2017; 89: 578. CrossRef
Eribulin in Advanced Breast Cancer: Safety, Efficacy and New Perspectives
Ornella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua, Marco C Merlano
Future Oncology.2017; 13(30): 2759. CrossRef
Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang, Qiong Zhao
Oncotarget.2017; 8(67): 112076. CrossRef

12,181 View
333 Download
6 Web of Science
9 Crossref

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study: Se Hyun Kim, Kyung Hae Jung, Tae-Yong Kim, Seock-Ah Im, In Sil Choi, Yee Soo Chae, Sun Kyung Baek, Seok Yun Kang, Sarah Park, In Hae Park, Keun Seok Lee, Yoon Ji Choi, Soohyeon Lee, Joo Hyuk Sohn, Yeon-Hee Park, Young-Hyuck Im, Jin-Hee Ahn, Sung-Bae Kim, Jee Hyun Kim; Cancer Res Treat. 2016;48(4):1373-1381. Published online March 23, 2016; DOI: https://doi.org/10.4143/crt.2015.475

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio (LNR) in patients with breast cancer after neoadjuvant chemotherapy.
Materials and Methods
This retrospective analysis is based on the data of 814 patientswith stage II/III breast cancer treated with four cycles of doxorubicin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical significance of LNR (3 categories: low 0-0.20 vs. intermediate 0.21-0.65 vs. high 0.66-1.00) using a Cox proportional regression model.
Results
A total of 799 patients underwent breast surgery. Pathologic complete response (pCR, ypT0/isN0) was achieved in 129 patients (16.1%) (hormone receptor [HR] +/human epidermal growth factor receptor 2 [HER2] –, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; triple negative breast cancer, 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range, 0 to 42) and 13.98 (range, 1 to 64), respectively. The mean LNR was 0.17 (low, 574 [71.8%]; intermediate, 170 [21.3%]; high, 55 [6.9%]). In univariate analysis, LNR showed significant association with a worse relapse-free survival (3-year relapse-free survival rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; p < 0.001, log-rank test). In multivariate analysis, LNR did not show significant association with recurrence after adjusting for other clinical factors (age, histologic grade, subtype, ypT stage, ypN stage, lymphatic or vascular invasion, and pCR). In subgroup analysis, the LNR system had good prognostic value in HR+/HER2– subtype.
Conclusion
LNR is not superior to ypN stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy. However, the prognostic value of the LNR system in HR+/HER2– patients is notable and worthy of further investigation.

Citations

Citations to this article as recorded by

Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System
Zhe Wang, Wei Chong, Huikun Zhang, Xiaoli Liu, Yawen Zhao, Zhifang Guo, Li Fu, Yongjie Ma, Feng Gu
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
Jinzhao Liu, Yifei Li, Weifang Zhang, Chenhui Yang, Chao Yang, Liang Chen, Mingjian Ding, Liang Zhang, Xiaojun Liu, Guozhong Cui, Yunjiang Liu
Frontiers in Surgery.2022;[Epub] CrossRef
Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
Yul Ri Chung, Ji Won Woo, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Scientific Reports.2021;[Epub] CrossRef
Using a novel T-lymph node ratio model to evaluate the prognosis of nonmetastatic breast cancer patients who received preoperative radiotherapy followed by mastectomy
Yang Wang, Yuanyuan Zhao, Song Liu, Weifang Tang, Hong Gao, Xucai Zheng, Shikai Hong, Shengying Wang
Medicine.2017; 96(42): e8203. CrossRef
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes
Xiang Li, Ruishan Zhang, Zhuangkai Liu, Shuang Li, Hong Xu
Oncotarget.2017; 8(12): 20252. CrossRef
Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
Ji Hyun Chang, Wan Jeon, Kyubo Kim, Kyung Hwan Shin, Wonshik Han, Dong-Young Noh, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Journal of Breast Cancer.2016; 19(4): 394. CrossRef

12,203 View
163 Download
7 Web of Science
6 Crossref

Case Reports

Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma: Hye Sook Kim, Soon Wook Lee, Yoon Ji Choi, Sang Won Shin, Yeul Hong Kim, Min Sun Cho, Soon Nam Lee, Kyong Hwa Park; Cancer Res Treat. 2015;47(3):534-538. Published online October 17, 2014; DOI: https://doi.org/10.4143/crt.2013.151

Abstract PDF PubReader ePub

We report a case of a 56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-cell lymphoma with a BRCA1 gene mutation. Evidence is mounting that there is a large increase in the risk for hematologic malignancies among patients with genetic changes in the BRCA pathways. The genomic analysis demonstrated a frameshift mutation in the BRCA1 gene: 277_279delinsCC (Phe93fs). It is a novel BRCA1 mutation that has never been reported, and caused malignant lymphoma as well as breast and ovarian cancer.

Citations

Citations to this article as recorded by

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi
BMC Cancer.2020;[Epub] CrossRef
Lymphoma in Australian Border Collies: survey results and pedigree analyses
KY Cheng, PXY Soh, PF Bennett, P Williamson
Australian Veterinary Journal.2019; 97(1-2): 14. CrossRef
Germline mutations predisposing to diffuse large B-cell lymphoma
O C Leeksma, N F de Miranda, H Veelken
Blood Cancer Journal.2017; 7(2): e532. CrossRef
Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation
Petra Škerl, Mateja Krajc, Ana Blatnik, Srdjan Novaković
Oncology Reports.2017; 38(1): 279. CrossRef
Risk of lymphoma subtypes by occupational exposure in Southern Italy
Giovanni Maria Ferri, Giorgina Specchia, Patrizio Mazza, Giuseppe Ingravallo, Graziana Intranuovo, Chiara Monica Guastadisegno, Maria Luisa Congedo, Gianfranco Lagioia, Maria Cristina Loparco, Annamaria Giordano, Tommasina Perrone, Francesco Guadio, Cater
Journal of Occupational Medicine and Toxicology.2017;[Epub] CrossRef
How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy
Bin Zhang, Xia Zhang, Minghuan Li, Li Kong, Xiaoqin Deng, Jinming Yu
Cancer Biology & Therapy.2016; 17(2): 125. CrossRef
Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients Finding Founder Mutations
Min Chul Choi, Jin-Hyung Heo, Ja-Hyun Jang, Sang Geun Jung, Hyun Park, Won Duk Joo, Chan Lee, Je Ho Lee, Jun Mo Lee, Yoon Young Hwang, Seung Jo Kim
International Journal of Gynecological Cancer.2015; 25(8): 1386. CrossRef

14,034 View
121 Download
6 Web of Science
7 Crossref

Bladder and Liver Involvement of Visceral Larva Migrans May Mimic Malignancy: Eun Joo Kang, Yoon Ji Choi, Jung Sun Kim, Byung Hyun Lee, Ka-Won Kang, Hong Jun Kim, Eun Sang Yu, Yeul Hong Kim; Cancer Res Treat. 2014;46(4):419-424. Published online July 18, 2014; DOI: https://doi.org/10.4143/crt.2013.104

Abstract PDF PubReader ePub

Visceral larva migrans (VLM) syndrome is a clinical manifestation of systemic organ involvement by Toxocara species. VLM with involvement of the bladder and liver is a rare finding. A 62-year-old woman presented with diffuse bladder wall thickening and multiple liver masses with peripheral eosinophilia and urinary symptoms. We considered malignancy or eosinophilic cystitis through clinical manifestations and imaging findings. However, no suspicious malignant lesions were observed on cystoscopy and liver mass biopsy revealed the presence of eosinophilic necrotizing granuloma without malignant cells. Anti-Toxocara antibodies were detected by western blotting and the patient was diagnosed with VLM syndrome. After taking prednisolone, urinary symptoms disappeared. On abdominal CT scan taken after three months, the size of multiple liver masses and bladder wall thickening had decreased. VLM syndrome should be suspected in patients with an atypical imaging pattern and peripheral eosinophilia.

Citations

Citations to this article as recorded by

Pulmonary and Liver Toxocariasis Mimicking Metastatic Tumors in a Patient with Colon Cancer
Miju Cheon, Jang Yoo
Diagnostics.2023; 14(1): 58. CrossRef
Eosinophilic Granuloma of the Liver Mimicking Metastatic Liver Tumor
Yotaro Uchida, Keiji Yokoyama, Tomotaka Higashi, Takanori Kitaguchi, Hiromi Fukuda, Ryo Yamauchi, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Hiroyuki Hayashi, Yoshi
Internal Medicine.2022; 61(10): 1511. CrossRef
Toxocariasis-associated urinary system diseases: a systematic review of reported cases
Ali Ardekani, Amirhossein Roshanshad, Seyed Ali Hosseini, Jean-François Magnaval, Ali Abdollahi, Ali Rostami
Transactions of The Royal Society of Tropical Medicine and Hygiene.2022; 116(7): 668. CrossRef
Toxocariasis Suspected of Having Infiltrated Directly from the Liver to the Lung through the Diaphragm
Masaki Kakimoto, Masayuki Murata, Fujiko Mitsumoto-Kaseida, Eiichi Ogawa, Yuji Matsumoto, Akira Kusaga, Kazuhiro Toyoda, Takeo Hayashi, Kazuya Ura, Keishi Kanno, Norihiro Furusyo, Susumu Tazuma
Internal Medicine.2019; 58(18): 2737. CrossRef
Klasyczne i nowoczesne metody diagnozowania toksokarozy u dzieci
Anna Kroteń, Artur Sulik, Elżbieta Ołdak
Pediatria Polska.2015; 90(4): 319. CrossRef

15,611 View
84 Download
5 Web of Science
5 Crossref

First
Prev
Page of 1
Next
Last

Search